Episode 4: How to build a physically healthy life in your 20s
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
30 minutes ago
- Zawya
Humansa Powers Chubb UTS Hong Kong 2025 with Humansa
Strategic Partnership with HKCTA Set to Elevate Tennis Development and Promote Health and Longevity in Hong Kong HONG KONG SAR- Media OutReach Newswire - 7 August 2025 - Humansa, Asia's premier health and longevity centre, is proud to be the Presenting Sponsor of Chubb UTS Hong Kong 2025 with Humansa, marking a significant milestone in its strategic partnership with the Hong Kong, China Tennis Association (HKCTA). The collaboration highlights Humansa's dedication to advancing tennis as a scientifically validated approach to longevity while introducing innovative health solutions that benefit athletes and fans. Humansa Supports Tennis: A Science-Backed Approach to Longevity At the core of Humansa's support for tennis lies our mission to extend healthspan and lifespan through evidence-based innovation. Tennis has been scientifically proven to be one of the most effective activities for longevity, with research indicating that participating in regular exercise such as tennis can potentially add up to 10 years to a person's lifespan. [1] This remarkable benefit stems from tennis's unique combination of aerobic and anaerobic exercise that enhances cardiovascular health and muscle strength, its high-intensity interval elements that improve metabolic function, and its inherent social engagement that reduces stress and supports cognitive health. By championing tennis in Hong Kong, Humansa reinforces its commitment to promoting scientifically validated longevity strategies, establishing the sport as a fundamental component of our wellness philosophy. A Shared Vision for Tennis Excellence and Longevity Humansa is collaborating with HKCTA in positioning Hong Kong as Asia's premier tennis destination. This comprehensive partnership extends beyond tournament sponsorship to include youth development programs that nurture junior talent, elite athlete support systems focusing on performance optimization and injury prevention, and community engagement initiatives that promote tennis as a lifelong health activity. The alliance represents a shared vision to elevate both the sport and the health benefits it delivers to Hong Kong's community. Mr. Michael Cheng, President of the HKCTA, said, "Our overriding mission is to promote tennis as a lifelong sport and to foster its growth across all levels in Hong Kong. Our vision is to build a dynamic tennis community while reinforcing Hong Kong's position as a leading sports and major event hub and tourist destination—driving Hong Kong's mega-events economy and establishing the city as a must-visit destination for regional and global travelers. The partnership with Humansa supports our efforts in highlighting the long-term health benefits of tennis and bringing greater visibility to the sport of tennis, whilst inspiring greater participation in sport across the whole community. " "Humansa's commitment to evidence-based wellness and longevity complements our goal of encouraging more people to embrace tennis, not only as a competitive sport but also as a sustainable lifestyle choice." Ultimate Tennis Showdown – Tennis like never before! Globally acclaimed, innovative, tennis event the Ultimate Tennis Showdown (UTS) will be making its grand Asian debut in Hong Kong on 14-15 October 2025. Founded by Coach Patrick Mouratoglou (@patrickmouratoglou), this fun, fast, furious and ferocious format will bring a new experience to Hong Kong tennis fans. Its all-star line-up, which includes Australia's top-ranked player and current World No. 8, 2024 UTS Grand Final London champion Alex de Minaur (@alexdeminaur); along with current world No. 11 player and 2024 UTS Oslo champion Andrey Rublev (@andreyrublev); Chinese star Zhang Zhizhen (@zizi_zhang96) ; and tennis fans' favourite, the Australian Nick Kyrgios (@k1ngkyrg1os). Hailing from the Czech Republic, 19-year-old Jakub Mensik (@ ranked No. 18, a next generation tennis star who made his UTS debut at this year's UTS Guadalajara before defeating Novak Djokovic in the Miami Masters 1000 final to claim the championship. Meanwhile, Latin America's top ranked Francisco Cerundolo (@francerundolo) also makes his UTS debut. Two more mystery player will be announced soon, stayed tuned! Humansa will provide UTS competitors with exclusive access to premium recovery and performance services during the tournament, including on-site physiotherapy and stretch therapy from our expert team. Players will also enjoy full access to Humansa Victoria Dockside for personalized pre- and post-event recovery programs. Valued Humansa members can join us for an exclusive VIP experiences which includes courtside seating, players interaction, behind the scene access, special wellness experiences at the Humansa Experience Zone, unique souvenirs, and much more! Racket Sports Longevity Series The partnership will see the introduction of Humansa's innovative Racket Sports Longevity Series, a tailored collection of services designed to enhance athletic performance and promote longevity. This groundbreaking series incorporates advanced AI-driven injury prevention technology, specialized recovery protocols for elite athletes, nutrition plans optimized for longevity, and comprehensive biomarker tracking to maintain peak performance levels. Don So, CEO of Humansa, explained the strategic thinking behind the collaboration: "Our partnership with the HKCTA and the UTS embodies our vision of integrating health innovation with sporting excellence. Tennis represents more than just competition—it's a proven longevity accelerator. By providing athletes and fans with scientifically validated solutions, we're helping them achieve superior performance, faster recovery, and extended healthspan." Humansa's involvement in Chubb UTS Hong Kong 2025 forms part of a sustained commitment to tennis development and its associated health benefits. Looking ahead, the company plans to collaborate with additional regional and international HKCTA events, establish youth development camps incorporating Humansa's wellness resources, and conduct joint research with HKCTA into athlete health, performance and longevity. Through these initiatives, Humansa reaffirms its dedication to helping individuals live healthier, longer lives by leveraging tennis as a powerful vehicle for longevity. [1] & Hashtag: #Humansa The issuer is solely responsible for the content of this announcement. About Humansa Humansa, Asia's first and leading one-stop health and longevity center, is transforming health and wellness with cutting-edge science, AI-driven insights, and personalized care. Founded in 2020 and based in Hong Kong, we operate over 40 centers, serving 80,000+ clients annually, empowering them to enjoy lives for as long as possible. Humansa's flagship store, located at Victoria Dockside, prioritizes prevention, health optimization, and education. By streamlining fragmented services, we empower individuals to proactively enhance their healthspan, delay aging, and achieve fulfilling lifestyles in a supportive, luxurious environment. We provide world-class health solutions, including women's health management, energy and vitality management, brain health, weight management, and children's development programs tailored to meet individual needs. About Hong Kong, China Tennis Association (HKCTA) The HKCTA is a National Sport Association formed in 1909 with 40 affiliated clubs, over 4,000 individual members and recognised by both the Asian Tennis Federation (ATF) and the International Tennis Federation (ITF). HKCTA's objectives are to promote tennis to all, to nurture talented players to compete at a regional and international level, and to raise the standard of the game in Hong Kong. To meet its objectives, HKCTA organises a number of local and international tennis tournaments as well as grassroots, junior and elite development programs, inter-club leagues, coaching certification courses and a Tennis-For-All open enrollment programme. For more information, please visit About UTS The growing popularity of the innovative and fast-paced format has seen the UTS Tour increase its worldwide reach in 2025. The UTS Tour made its debut this year in Latin America in February with UTS Guadalajara. The hugely successful Bastide Medical UTS Nîmes was played in front of sell-out crowds in the iconic Arénes des Nîmes Roman ampitheatre. Since its creation, UTS has attracted many of the world's best players, including Top 10 stars Holger Rune, Taylor Fritz, Stefanos Tsitsipas, Lorenzo Musetti, Casper Ruud, Frances Tiafoe and Nick Kyrgios, all attracted to the fun, fast, furious and ferocious format. The 2025 UTS Grand Final will return to London once again. This will be the third year in a row that London has hosted the UTS season finale. Humansa Health
Zawya
2 hours ago
- Zawya
Study finds long-term health benefits from bariatric surgery and liver transplant
Dubai, United Arab Emirates - Simultaneous bariatric surgery and liver transplant for patients who are severely obese is safe and improves long-term health outcomes, according to a recent Mayo Clinic study. This combined approach offers a needed solution for these patients who are often denied a lifesaving liver transplant due to their weight. The 10-year study, published in the Journal of Hepatology, compared patients who received only a liver transplant with those who underwent both a liver transplant and bariatric surgery. The combined approach resulted in sustained weight loss, reduced risk of type 2 diabetes and lower risk of fatty liver disease recurrence. Importantly, the combined procedure posed no additional risks compared to liver transplant alone. "We've been amazed by the transformation our patients experience," says Julie Heimbach, M.D., director of Mayo Clinic Transplant Center in Minnesota and the study's senior author. "This dual approach prevents long-term obesity complications like diabetes, heart disease and cancer, while also preventing fatty liver disease recurrence." How obesity and liver disease are connected The percentage of liver transplant candidates in the U.S. with obesity continues to climb, with more than 41% of candidates having a body mass index above 30 in 2022. Obesity puts people at risk of developing metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease. It's a condition where excess fat accumulates in the liver, which can lead to inflammation, scarring and advanced liver disease. Patients with a body mass index of 40 are more likely to be denied a transplant due to their weight. "Since MASLD is a leading cause of liver failure, it only makes sense to protect the precious, lifegiving new liver from the same damage that led to the patient needing a transplant in the first place. Safely combining the two procedures protects the transplanted liver and can provide profound health benefits to these patients," says Todd Kellogg, M.D., Mayo Clinic bariatric surgeon and the study's co-author. What about using new prescription medications for weight loss? New weight loss medications, such as GLP-1s, are being used to help some pre-transplant and post-transplant patients manage their weight. Still, Mayo Clinic experts say bariatric surgery remains an important option for patients with severe obesity due to its safety, proven effectiveness and lasting results. Another recent Mayo study related to kidney transplant patients supports this. "The patients that we're talking about really have a significant amount of extra weight. The issue with the GLP-1 medications is they are effective in terms of weight loss as well as other benefits which are being identified, but they may not get these patients with severe obesity to their lasting goal of a healthier weight," Dr. Heimbach says. Bringing together experts from different medical specialties is essential when treating these patients, says Ty Diwan, M.D., Mayo Clinic transplant surgeon and the study's co-author. "This study shows that caring for these complex patients extends beyond the transplant itself," Dr. Diwan says. "Multidisciplinary care is required to maximize patient outcomes, and that is what we see in this data. By bringing together experts in very different fields, we've improved patient care and overall health outcomes."
Zawya
2 hours ago
- Zawya
Burjeel reports 129% increase in Q2 net profit, revenue grows 18.7%
UAE - Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, has delivered a strong top-line growth of 18.7% to AED1,403 million ($381.98 million) in Q2 2025, driven by a 12.1% increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network. Revenue in H1'25 rose 12.2% to AED2,677 million, with total patient visits reaching 3.4 million, the healthcare provider said. EBITDA rose 59.4% to AED306 million in Q2 2025, fueled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes AED72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The EBITDA margin expanded 5.6 p.p. to 21.8%. In H1'25, EBITDA increased 14.2% to AED487 million, with a margin of 18.2%. Net profit surged 128.9% to AED148 million ($40.29 million) in Q2' 2025, reflecting margin expansion, enhanced operating leverage, and asset optimization. In H1'25, net profit rose 10.6% to AED187 million. Specialised Services, expansion Burjeel Holdings accelerated its strategic execution in Q2 2025 with a series of high-impact initiatives that deepened specialisation and broadened patient access. The group expanded its advanced oncology network, integrating Dubai's Advanced Care Oncology Center and opening new Burjeel Cancer Institute (BCI) clinics in Al Ain, Sharjah, and Oman, reinforcing its position as a regional leader in complex cancer care. The UAE's first dedicated cancer pharmacy was also inaugurated, strengthening oncology support infrastructure. In parallel, Burjeel launched a regional mental health platform through its joint venture Alkalma, opening four specialist mental health centers across the UAE and Saudi Arabia. This marked the first phase of a multi-year expansion strategy aimed at addressing rising demand for mental wellness services. In Saudi Arabia, the Group acquired a major physiotherapy facility in Riyadh under the PhysioTherabia platform, adding scale and unlocking turnaround potential through secured government contracts. Investments in operational resilience and access continued with the AED170 million acquisition of the Medeor Hospital Dubai building, converting long-term lease obligations into ownership and enhancing cost structure flexibility. The group also expanded its primary care footprint with a new medical center launched on Saadiyat Island, aligning with its growth strategy in high-yield urban catchments. In medical innovation, Burjeel launched Docktour, a transformative healthcare logistics joint venture with AD Ports Group, aiming to redefine how medical services and infrastructure are delivered to underserved and remote communities. Several specialised centers were introduced, including the region's first Al Muderis Osseointegration Clinic for advanced limb reconstruction, a state-of-the-art Epilepsy Monitoring Unit, and expanded capabilities in rare diseases, hematology, and metabolic research. Additionally, the Group continued its digital transformation with AI-powered diagnostics and led groundbreaking research in microgravity, aiming to transform care for patients with diabetes in space and on Earth. John Sunil, Chief Executive Officer of Burjeel Holdings, said: 'The second quarter delivered exceptionally strong results, with 19% revenue growth driven by a 12% increase in patient footfall and improved yield. EBITDA rose by 59%, accompanied by a margin uplift to 22%. This robust performance significantly strengthened the first-half outcome, underscoring Burjeel Holdings' resilience and long-term sustainable growth. 'These results reflect tangible progress in key operational areas such as physician manpower optimization, formulary management, and cost control, while our strategic focus on super-specialty care is beginning to yield measurable benefits, enhancing both revenue and profitability. We continue to invest in high-value services and next-generation care facilities to support long-term momentum. 'We also advanced key strategic priorities, reinforcing leadership in complex care across oncology, transplants, fertility, mental health, and diagnostics. Our oncology platform is now the UAE's largest private network, featuring new cancer clinics and cell and gene therapy capabilities. The Alkalma mental health platform is scaling regionally, alongside rehabilitation services through over 30 PhysioTherabia centers in Saudi Arabia. Additionally, we introduced the region's first Osseointegration Clinic for cutting-edge prosthetic care. 'In parallel with expanding our network of primary care and medical centers, we deepened partnerships with government and corporate stakeholders and accelerated digital integration through Oracle Health EMR and AI-powered tools. Building on this platform, we entered into pivotal partnerships in oncology, value-based care, diagnostics, and international healthcare innovation, establishing the Group as the healthcare partner of choice. 'Burjeel Holdings is uniquely positioned to capture significant opportunities across the region, supported by rising demand for complex care and a growing population. Our focus remains on converting recent investments into sustained expansion and margin improvement, while maintaining disciplined financial management to support long-term shareholder value. Net profit growth of 129% in the reporting quarter reinforces this trajectory and strengthens the foundation for consistent shareholder returns.' Growth drivers Oncology remained a core growth driver, with revenue rising 36.7% in Q2'25 and 38.1% in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18%), emergency medicine (+17%), cardiology (+16%), and gastroenterology (+13%). Inpatient footfall rose 17.7% in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. The group performed 22,930 surgeries, up 18.7%, with momentum concentrated at Burjeel Medical City, Burjeel Specialty Hospital Sharjah, Lifecare Hospital Musaffah and Burjeel Royal Hospital Al Ain. Bed occupancy improved to 69%, up from 65% a year ago, and averaged 69% in H1'25. Inpatient volumes rose 14.6% over the first half. Outpatient footfall grew 12.0% in Q2'25, accelerating from 5.2% in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilization improved to 68%, up from 65% in Q1'25, enabled by optimized hiring and scaling of clinical teams. Leading facilities included Burjeel Medical City, Lifecare Hospital Baniyas, and Burjeel Day Surgery Center Barari. In H1'25, outpatient volumes increased 8.6%.
